By understanding the absolute risk and putting the numbers from trials into a normal frequency, people can better understand the impact of medications and make more informed decisions about treatment options
Patients who are pregnant or breastfeeding, have a history of medullary thyroid cancer or MEN-2 syndrome, severe gastroparesis, or certain pancreatic conditions may not be candidates
The proportion of patients receiving 3.0-mg oral semaglutide at index was higher than that recorded in the study by Aroda et al., which showed that 51.7% of the study population received the 3.0-mg formulation alone at first prescription, while 25.7% and 5.2% received the 7.0 mg and 14.0 mg formulations, respectively [18]
Anyone who is invested in their gut health should be paying attention to L-Glutamine.
But Ozempics reign on top looks to be coming to a close, if it isnt already here